Assessing Brown & Brown (BRO) Valuation After Mixed Returns And A 20.8% Undervaluation Narrative

Brown & Brown stock: recent returns and business mix

Brown & Brown (BRO) has drawn investor attention after a period of mixed share performance, with the stock showing negative total returns over the past year alongside multi year gains and solid reported revenue and net income figures.

See our latest analysis for Brown & Brown.

At a share price of US$65.95, Brown & Brown has seen short term share price pressure with a 30 day share price return of 8.61% and year to date share price return of 15.03% decline. Multi year total shareholder returns of 13.77% over three years and 44.10% over five years point to longer term gains that contrast with the 46.61% total shareholder return decline over the past year, suggesting recent momentum has faded as investors reassess growth prospects and risk.

If you are weighing Brown & Brown against other ideas in your portfolio, this can be a useful moment to broaden your search with 20 top founder-led companies

With Brown & Brown trading at US$65.95, some data points hint at a possible discount, including an intrinsic value gap and a lower price than analyst targets. This raises the question of whether there is genuine upside here or if the market is already pricing in future growth.

Most Popular Narrative: 20.8% Undervalued

The most followed narrative for Brown & Brown pegs fair value at $83.29, above the last close of $65.95. This frames the current discount as valuation driven rather than purely sentiment driven.

Strong cash flow from operations, combined with a strategic focus on leveraging a diversified portfolio across geographies and lines of business, positions the company to navigate economic uncertainties and potentially increase future earnings stability and growth.

Read the complete narrative.

Want to see what is baked into that premium fair value? The narrative leans on steady revenue expansion, resilient margins, and a future earnings multiple usually reserved for faster growing sectors.

Result: Fair Value of $83.29 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story can change quickly if economic or legislative shifts hit insurance demand, or if rising medical and pharmacy costs squeeze margins in key benefits lines.

Find out about the key risks to this Brown & Brown narrative.

Another Way To Look At Brown & Brown's Valuation

The first narrative focuses on discounted cash flows and fair value estimates, but the current P/E of 21.5x tells a different story. It is well above the US Insurance industry at 11.3x and the fair ratio estimate of 13.5x, yet below peer averages of 35.3x. This leaves you weighing potential upside against valuation risk.

To see how these valuation gaps compare in practice, including what the fair ratio implies if the market moves closer to it, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on value and recent returns can leave the picture feeling unclear. It can make sense to move quickly, review the underlying data yourself, and weigh both sides of the story with 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Brown & Brown is on your radar, do not stop there. Use the screeners below to quickly surface other stocks that might fit your style.

• Spot potential value opportunities early by checking stocks highlighted in the 62 high quality undervalued stocks.
• Prioritise resilience and sleep better at night by focusing on companies identified in the 67 resilient stocks with low risk scores.
• Hunt for overlooked opportunities by scanning the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com